|
Report Date : |
21.06.2014 |
IDENTIFICATION DETAILS
|
Name : |
NAMIKI SHOJI CO LTD |
|
|
|
|
Registered Office : |
Kensei Shinjuku Bldg 3F, 5-5-3 Shinjuku Shinjukuku Tokyo 160-0022 |
|
|
|
|
Country : |
Japan |
|
|
|
|
Financials (as on) : |
31.05.2013 |
|
|
|
|
Date of Incorporation : |
November 1974 |
|
|
|
|
Com. Reg. No.: |
0111-01-015528 |
|
|
|
|
Legal Form : |
Limited Company
(Kabushiki Kaisha) |
|
|
|
|
Line of Business : |
Import, wholesale of pharmaceuticals, reagents, drug-discovery
compounds |
|
|
|
|
No. of Employees |
40 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
COMPANY NAME AND
ADDRESS
NAMIKI SHOJI CO LTD
REGD NAME: Namiki
Shoji KK
MAIN OFFICE: Kensei
Shinjuku Bldg 3F, 5-5-3 Shinjuku Shinjukuku Tokyo 160-0022 JAPAN
Tel: 03-3354-4026
Fax: 03-3352-2196
*.. Moved to the caption
address in 2006 from the former one as given
URL: http://www.namiki.co.jp
E-Mail address: info@namiki.co.jp
ACTIVITIES
Import, wholesale
of pharmaceuticals, reagents, drug-discovery compounds, etc
BRANCHES
Osaka
OFFICERS
TATSUYA NAMIKI,
PRES
Tohru Yokoyama,
s/mgn dir
Yen Amount: In million Yen, unless otherwise stated
SUMMARY
FINANCES FAIR A/SALES Yen 2,220 M
PAYMENTS NO COMPLAINTS CAPITAL Yen
40 M
TREND SLOW WORTH Yen 2,420 M
STARTED 1974 EMPLOYES 40
COMMENT
TRADING FIRM SPECIALIZING IN
PHARMACEUTICALS.
FINANCIAL SITUATION CONSIDERED FAIR AND GOOD
FOR ORDINARY BUSINESS ENGAGEMENTS.
HIGHLIGHTS
The subject company is a trading firm for import and wholesale of
pharmaceuticals, reagents, drug-discovery compounds, intermediates, health
foods, other. Clients include
pharmaceutical makers, wholesalers, chain stores, other.
FINANCIAL INFORMATION
Financials are disclosed only partially.
The sales volume for May/2013 fiscal term amounted to Yen 2,220 million,
a 2% down from Yen 2,253 million in the previous term. High Yen hurt imports by reducing earnings in
Yen terms. The net profit was posted at
Yen 140 million, compared with Yen 117 million a year ago.
For the term that ended May 2014 the net profit was projected at Yen 150
million, on a 5% rise in turnover, to Yen 2,330 million. Weaker Yen may have raised sales in Yen
terms. Final results are yet to be
released.
The financial situation is considered FAIR
and good for ORDINARY business
engagements.
REGISTRATION
Date Registered: Nov
1974
Regd No.:
0111-01-015528 (Tokyo-Shinjukuku)
Legal Status: Limited Company (Kabushiki Kaisha)
Authorized: 320,000 shares
Issued: 80,000 shares
Sum: Yen 40 million
Major
shareholders (%): Tatsuya Namiki, others (Breakdown unavailable)
No.
of shareholders: 19
Nothing
detrimental is known as to the commercial morality of executives.
OPERATION
Activities: Imports and
wholesales pharmaceuticals, reagents, intermediates, drug-discovery compounds,
health foods, other (--100%)
Clients: [Mfrs,
wholesalers] Astellas Pharma Inc,
Daiichi Sankyo Co, Takeda Chemical Ind, Hisamitsu Pharmaceutical Co Inc, Sawai
Pharmaceutical Co, other
No. of accounts:
300
Domestic areas of
activities: Nationwide
Suppliers: [Mfrs,
wholesalers] Thermo Fisher Scientific KK, Sumitomo Chemical, Sundia, Taisho
Pharm Ind, Enamine Co, other
Payment record: No complaints
Location: Business area in
Tokyo. Office premises at the caption
address are leased and maintained satisfactory.
Bank References:
MUFG (Shinjuku)
SMBC (Shinjuku)
Relations:
Satisfactory
FINANCES
(In Million
Yen)
|
Terms Ending: |
|
31/05/2014 |
31/05/2013 |
31/05/2012 |
31/05/2011 |
|
Annual
Sales |
|
2,330 |
2,220 |
2,253 |
2,252 |
|
Recur.
Profit |
|
.. |
.. |
.. |
.. |
|
Net
Profit |
|
150 |
140 |
117 |
152 |
|
Total
Assets |
|
|
N/A |
N/A |
N/A |
|
Net
Worth |
|
|
2,420 |
2,280 |
2,163 |
|
Capital,
Paid-Up |
|
|
40 |
40 |
40 |
|
Div.P.Share(¥) |
|
|
0.00 |
0.00 |
0.00 |
|
<Analytical Data> |
(%) |
(%) |
(%) |
(%) |
|
|
S.Growth Rate |
4.95 |
-1.46 |
0.04 |
6.23 |
|
|
Current Ratio |
.. |
.. |
.. |
||
|
N.Worth Ratio |
.. |
.. |
.. |
||
|
N.Profit/Sales |
6.44 |
6.31 |
5.19 |
6.75 |
|
Notes: Financials
are only partially disclosed.
Forecast (or
estimated) figures for the 31/05/2014 fiscal term.
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall
operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.